The global market for over the counter drugs and dietary supplements reached $164.7 billion in 2016 and should reach $220.8 billion in 2021, with a compound annual growth rate of 6.0%. The study goal of this report is to understand the OTC drugs and dietary supplement market and provide five-year forecasts for the same. The objective of the study i
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the U.S. Food and Drug Administration does not object to Egalet's distribution of promotional materials and communications to healthcare professionals...
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Capecitabine Tablets, 150& 500 mg, an AB-rated generic vers
In addition, you should read the "Risk Factors" section of this Annual Report on Form 10- K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this Annual Report on Fo
The FMD comes into effect across Europe in 2019 and requires barcoding and tamper-evident seals on all prescription and over-the-counter medicine primary packages. Covectra President Steve Wood said: Since barcodes can be easily copied, this new solution makes counterfeiting virtually impossible which is especially critical when it comes to the...
PuraCap Laboratories LLC will expand its Franklin operations with a $2.5 million investment, creating 30 full-time jobs according to Gov. The project comes nearly a year after PuraCap purchased Blu Pharmaceuticals LLC, a privately held generic pharmaceutical company. PuraCap Laboratories is a subsidiary of PuraCap International LLC in Piscataway, N
TARRYTOWN, N.Y. and PARIS, March 28, 2017/ PRNewswire/ Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved DUPIXENT Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled
Sanofi and Regeneron Announce FDA Approval of Dupixent, the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis- Dupixent will be available later this week to U.S. patients suffering from this chronic and debilitating form of eczema- Paris, France and Tarrytown, New York- March 28, 2017- Sanofi and Regeneron Pharmac
Ipsen today announced that its 2016 Registration Document has been filed with the French Autorit des Marchs Financiers on 27 March 2017 and registered under the number D.17-0231. Ipsen is a global specialty-driven pharmaceutical group with total sales close to ?1.6 billion in 2016. Ipsen sells more than 20 drugs in more than 115 countri
But with a 45- count package of Claritin, a non-drowsy allergy treatment, costing $26 and the heartburn medicine Zantac costing $25 for a 65- count package, some people spend as much money out of pocket purchasing these drugs than similar prescription medicines. MedAssist's Over the Counter Medicine Give Away Day many arriving hours before the e
Release date- 23032017- OSAKA, Japan, FLORHAM PARK, N.J. and STAMFORD, Conn.- Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration approved Symproic 0.2 mg tablets C-II as a once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation in adul
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Nonprescription Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss safety issues associated with over-the-counter analgesic combination products used for upset stomach and hangover indications under the...
On March 20, 2017 the Over-the-Counter Hearing Aid Act of 2017 was introduced by Senators Elizabeth Warren, Charles Grassley, Maggie Hassan and Johnny Isakson. Representatives Joseph Kennedy III and Marsha Blackburn have introduced an Over-the-Counter Hearing Aid bill in the House, which mirrors the Senate bill. If the FDA creates an OTC hearing ai
By a News Reporter-Staff News Editor at Pharma Business Week Innovus Pharmaceuticals, Inc., announced the pricing of a public offering of 25,666,669 shares of common stock, one-year warrants to purchase up to 25,666,669 shares of common stock and five-year warrants to purchase up to 25,666,669 shares of common stock, with expected total gross pro
Innovus Pharmaceuticals, Inc., today announced that it has received a Notice of Intention to Grant from the European Patent Office to issue a European-wide patent entitled Sensitization composition and method of use for its Sensum+ product, for reduced penile sensitivity. On March 8, 2017, Innovus Pharma announced that it received the CPNP
OncBioMune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to inform shareholders that sales in Mexico of the Company's licensed products, Bekunis for constipation and Cirkused for stress, exceeded projections during the firs
By a News Reporter-Staff News Editor at Pharma Business Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Sebree, Terri B.; Pierce, Mark; O'neill, Carol, filed on September 26, 2014, was published online on March 14, 2017. The patent's assignee for patent number 9592291 is Teva Pharmaceuticals International
OSAKA, Japan& FLORHAM PARK, N.J.& STAMFORD, Conn. Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration approved Symproic 0.2 mg tablets C-II as a once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation in adult patients with chron
Unless otherwise indicated, references in this Quarterly Report on Form 10- Q to "we," "us," and "our" are to the Company, unless the context requires otherwise. The following discussion and analysis by our management of our financial condition and results of operations should be read in conjunction with our unaudited condensed interim financial st
The Over-the-Counter Drugs and Dietary Supplements: Global Markets Report Includes:- An overview of the global markets for OTC drugs and dietary supplements- Analyses of global market trends, with data from 2015, 2016, and projections of CAGRs through 2021- Information about how pharmacies affect the OTC drug market- Analysis of new developments th
VANC Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets provides marketing update as part of its ongoing program to bring value added products to the Canadian pharmacy industry. "I am pleased to announce that VANC's premium natural iron supplement Hema-Fer? has been accepted by two ph
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, today reported financial results for the quarter and year ended Jan. 31, 2017, and will provide an update on the company's clinical development efforts and highlights from the year. "We are pleased to report that last year was a very product
The overall safety and efficacy of supplements sold in the U.S. is ensured through a strong and complex framework of federal regulations, industry-adopted best practices, and the inherent safety of ingredients used in supplement. Supplement companies are also required to register manufacturing facilities with the FDA and FDA regularly inspects...
Medical research firm IMS Health data shows the value of the medical market increased by 7.49 percent to $5 billion in 2016 thanks to robust growth of unbranded generic medicine. The market for unbranded medicine grew by 18 percent, the highest among other types, said Jorge Wagner, chairman of International Pharmaceutical Manufacturers Group, durin